Patrick Schöffski

43.5k total citations · 7 hit papers
510 papers, 19.4k citations indexed

About

Patrick Schöffski is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Gastroenterology. According to data from OpenAlex, Patrick Schöffski has authored 510 papers receiving a total of 19.4k indexed citations (citations by other indexed papers that have themselves been cited), including 315 papers in Pulmonary and Respiratory Medicine, 224 papers in Oncology and 136 papers in Gastroenterology. Recurrent topics in Patrick Schöffski's work include Sarcoma Diagnosis and Treatment (162 papers), Gastrointestinal Tumor Research and Treatment (136 papers) and Gastric Cancer Management and Outcomes (78 papers). Patrick Schöffski is often cited by papers focused on Sarcoma Diagnosis and Treatment (162 papers), Gastrointestinal Tumor Research and Treatment (136 papers) and Gastric Cancer Management and Outcomes (78 papers). Patrick Schöffski collaborates with scholars based in Belgium, Germany and United States. Patrick Schöffski's co-authors include Jean‐Yves Blay, Maria Dêbiec‐Rychter, Agnieszka Woźniak, Raf Sciot, Herlinde Dumez, Jaap Verweij, Hans Gelderblom, Pascal Wolter, Sandrine Marréaud and Axel Le Cesne and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Patrick Schöffski

492 papers receiving 19.1k citations

Hit Papers

Cabozantinib in Progressi... 2004 2026 2011 2018 2013 2014 2004 2016 2009 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Cabozantinib in Progressive Medullary Thyroid Cancer
    2013 850 citations Rossella Elisei, Martin Schlumberger et al. Journal of Clinical Oncology profile →
  2. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
    2014 814 citations Jaap Verweij, Patrick Schöffski et al. profile →
  3. Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer
    2004 616 citations Patrick Schöffski et al. Journal of Clinical Oncology profile →
  4. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
    2016 539 citations Patrick Schöffski, Sant P. Chawla et al. profile →
  5. Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
    2009 535 citations Stefan Sleijfer, Isabelle Ray‐Coquard et al. Journal of Clinical Oncology profile →
  6. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
    2017 429 citations Patrick Schöffski et al. profile →
  7. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial
    2020 251 citations Jean‐Yves Blay, Patrick Schöffski et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Patrick Schöffski 9.6k 9.5k 4.8k 3.2k 2.7k 510 19.4k
Allan T. van Oosterom 9.3k 1.0× 10.1k 1.1× 4.5k 0.9× 4.3k 1.3× 3.3k 1.2× 89 21.9k
Isabelle Ray‐Coquard 7.0k 0.7× 5.5k 0.6× 2.8k 0.6× 3.6k 1.1× 2.3k 0.9× 418 16.7k
Ian Judson 10.8k 1.1× 16.5k 1.7× 6.0k 1.2× 5.0k 1.6× 6.4k 2.3× 403 28.0k
Robert S. Benjamin 11.8k 1.2× 14.0k 1.5× 3.9k 0.8× 4.2k 1.3× 3.3k 1.2× 490 25.6k
Antoîne Italiano 9.0k 0.9× 9.2k 1.0× 4.0k 0.8× 2.6k 0.8× 684 0.3× 618 17.5k
David P. Kelsen 8.9k 0.9× 6.3k 0.7× 3.1k 0.6× 4.2k 1.3× 1.1k 0.4× 292 14.6k
John Zalcberg 9.7k 1.0× 8.0k 0.8× 3.0k 0.6× 5.5k 1.7× 2.9k 1.1× 410 18.5k
Stefano Cascinu 11.2k 1.2× 7.3k 0.8× 4.2k 0.9× 3.4k 1.1× 1.1k 0.4× 648 18.3k
Suzanne George 3.7k 0.4× 6.8k 0.7× 1.8k 0.4× 2.1k 0.7× 4.0k 1.5× 257 11.7k
Jeeyun Lee 7.6k 0.8× 6.7k 0.7× 3.4k 0.7× 3.1k 1.0× 1.6k 0.6× 506 14.4k

Countries citing papers authored by Patrick Schöffski

Since Specialization
Citations

This map shows the geographic impact of Patrick Schöffski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Schöffski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Schöffski more than expected).

Fields of papers citing papers by Patrick Schöffski

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Schöffski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Schöffski. The network helps show where Patrick Schöffski may publish in the future.

Co-authorship network of co-authors of Patrick Schöffski

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick Schöffski. A scholar is included among the top collaborators of Patrick Schöffski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick Schöffski. Patrick Schöffski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cornillie, Jasmien, Agnieszka Woźniak, Péter Pokreisz, et al.. (2017). In Vivo Antitumoral Efficacy of PhAc-ALGP-Doxorubicin, an Enzyme-Activated Doxorubicin Prodrug, in Patient-Derived Soft Tissue Sarcoma Xenograft Models. Molecular Cancer Therapeutics. 16(8). 1566–1575. 16 indexed citations
2.
Demetri, George D., Patrick Schöffski, Giovanni Grignani, et al.. (2017). Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. Journal of Clinical Oncology. 35(30). 3433–3439. 129 indexed citations
3.
Gebreyohannes, Yemarshet K., Patrick Schöffski, Thomas Van Looy, et al.. (2016). Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations. Molecular Cancer Therapeutics. 15(12). 2845–2852. 29 indexed citations
4.
Boichuk, Sergei, Kathleen R. Makielski, Agnieszka Woźniak, et al.. (2014). Unbiased Compound Screening Identifies Unexpected Drug Sensitivities and Novel Treatment Options for Gastrointestinal Stromal Tumors. Cancer Research. 74(4). 1200–1213. 37 indexed citations
5.
Woźniak, Agnieszka, Piotr Rutkowski, Patrick Schöffski, et al.. (2014). Tumor Genotype Is an Independent Prognostic Factor in Primary Gastrointestinal Stromal Tumors of Gastric Origin: A European Multicenter Analysis Based on ConticaGIST. Clinical Cancer Research. 20(23). 6105–6116. 121 indexed citations
6.
Looy, Thomas Van, Agnieszka Woźniak, Giuseppe Floris, et al.. (2014). Phosphoinositide 3-Kinase Inhibitors Combined with Imatinib in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors: Rationale and Efficacy. Clinical Cancer Research. 20(23). 6071–6082. 42 indexed citations
7.
Moreno, Víctor, David Olmos, Carlos Gomez‐Roca, et al.. (2014). Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study. Clinical Cancer Research. 20(22). 5663–5671. 14 indexed citations
8.
Elisei, Rossella, Martin Schlumberger, Stefan Müller, et al.. (2013). Cabozantinib in Progressive Medullary Thyroid Cancer. Journal of Clinical Oncology. 31(29). 3639–3646. 850 indexed citations breakdown →
9.
Boichuk, Sergei, Joshua A. Parry, Kathleen R. Makielski, et al.. (2013). The DREAM Complex Mediates GIST Cell Quiescence and Is a Novel Therapeutic Target to Enhance Imatinib-Induced Apoptosis. Cancer Research. 73(16). 5120–5129. 77 indexed citations
10.
Smyth, Tomoko, Thomas Van Looy, Jayne Curry, et al.. (2012). The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor Models. Molecular Cancer Therapeutics. 11(8). 1799–1808. 49 indexed citations
11.
Floris, Giuseppe, Agnieszka Woźniak, Raf Sciot, et al.. (2012). A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment Withdrawal. Clinical Cancer Research. 19(3). 620–630. 59 indexed citations
12.
Demetri, George D., Patrick Schöffski, Manisha H. Shah, et al.. (2012). Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure. Clinical Cancer Research. 18(11). 3170–3179. 102 indexed citations
13.
Baselga, José, Alain C. Mita, Patrick Schöffski, et al.. (2012). Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788. Clinical Cancer Research. 18(22). 6364–6372. 14 indexed citations
14.
Floris, Giuseppe, Maria Dêbiec‐Rychter, Agnieszka Woźniak, et al.. (2011). The Heat Shock Protein 90 Inhibitor IPI-504 Induces KIT Degradation, Tumor Shrinkage, and Cell Proliferation Arrest in Xenograft Models of Gastrointestinal Stromal Tumors. Molecular Cancer Therapeutics. 10(10). 1897–1908. 37 indexed citations
15.
Floris, Giuseppe, Raf Sciot, Agnieszka Woźniak, et al.. (2011). The Novel HSP90 Inhibitor, IPI-493, Is Highly Effective in Human Gastrostrointestinal Stromal Tumor Xenografts Carrying Heterogeneous KIT Mutations. Clinical Cancer Research. 17(17). 5604–5614. 41 indexed citations
16.
Lagarde, Pauline, Gaëlle Pérot, Audrey Kauffmann, et al.. (2011). Mitotic Checkpoints and Chromosome Instability Are Strong Predictors of Clinical Outcome in Gastrointestinal Stromal Tumors. Clinical Cancer Research. 18(3). 826–838. 102 indexed citations
17.
Dewaele, Barbara, Giuseppe Floris, Christopher Fletcher, et al.. (2010). Coactivated Platelet-Derived Growth Factor Receptor α and Epidermal Growth Factor Receptor Are Potential Therapeutic Targets in Intimal Sarcoma. Cancer Research. 70(18). 7304–7314. 68 indexed citations
18.
DePrimo, Samuel E., Xin Huang, Martin E. Blackstein, et al.. (2009). Circulating Levels of Soluble KIT Serve as a Biomarker for Clinical Outcome in Gastrointestinal Stromal Tumor Patients Receiving Sunitinib following Imatinib Failure. Clinical Cancer Research. 15(18). 5869–5877. 38 indexed citations
19.
Sleijfer, Stefan, Isabelle Ray‐Coquard, Zsuzsa Pápai, et al.. (2009). Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043). Journal of Clinical Oncology. 27(19). 3126–3132. 535 indexed citations breakdown →
20.
Floris, Giuseppe, Maria Dêbiec‐Rychter, Raf Sciot, et al.. (2009). High Efficacy of Panobinostat Towards Human Gastrointestinal Stromal Tumors in a Xenograft Mouse Model. Clinical Cancer Research. 15(12). 4066–4076. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Allan T. van Oosterom Breakdown of academic impact, for papers by Isabelle Ray‐Coquard Breakdown of academic impact, for papers by Ian Judson Breakdown of academic impact, for papers by Robert S. Benjamin Breakdown of academic impact, for papers by Antoîne Italiano Breakdown of academic impact, for papers by David P. Kelsen Breakdown of academic impact, for papers by John Zalcberg Breakdown of academic impact, for papers by Stefano Cascinu Breakdown of academic impact, for papers by Suzanne George Breakdown of academic impact, for papers by Jeeyun Lee
Rankless by CCL
2026